ﺑﺎﺯﮔﺸﺖ ﺑﻪ ﺻﻔﺤﻪ ﻗﺒﻠﯽ
خرید پکیج
تعداد آیتم قابل مشاهده باقیمانده : 3 مورد
نسخه الکترونیک
medimedia.ir

Periodontal disease in children: Associated systemic conditions

Periodontal disease in children: Associated systemic conditions
Literature review current through: May 2024.
This topic last updated: Jul 15, 2022.

INTRODUCTION — Soft tissue lesions of the oral cavity are common in children, and distinguishing between findings that are normal and those that are indicative of gingivitis, periodontal disease, local or systemic infection, and potentially life-threatening systemic conditions is important. The loss of periodontal attachment in children, manifest by tooth mobility or premature loss, can be a symptom of neoplasia, immunodeficiency, or metabolic defects [1,2]. The early detection and treatment of these conditions can be life-saving.

Systemic conditions associated with childhood periodontitis will be reviewed here. Soft tissue lesions and periodontitis not associated with systemic conditions are discussed separately. (See "Soft tissue lesions of the oral cavity in children" and "Gingivitis and periodontitis in children and adolescents".)

LANGERHANS CELL HISTIOCYTOSIS — Langerhans cell histiocytosis (LCH; previously known as histiocytosis X or eosinophilic granuloma) is a rare disorder that affects infants, children, and young adults and is characterized by histiocytic infiltration of the bones, skin, liver, or other organs [3,4]. (See "Clinical manifestations, pathologic features, and diagnosis of Langerhans cell histiocytosis".)

LCH presents with single- or multiple-site involvement. The skin, oral mucosa, bone, and lymph nodes are typical locations for single-site involvement. Multisite involvement occurs in the liver, spleen, lungs, bone marrow, and gastrointestinal and central nervous systems.

Between 20 and 30 percent of patients present with infiltration of the oral cavity, usually the posterior mandible [3,5]. The typical dental presentation of LCH is eruption of the primary molars at or soon after birth (picture 1). Additional oral manifestations include pain; ulceration; enlargement, inflammation, or recession of the gingiva; and mobility of teeth because of expansion of the alveolar bone [6-8]. In a case series of nine patients, the most common oral manifestation was ulceration on the hard palate [8]. Dental radiographs may show discrete, destructive bone lesions that make the teeth appear to be "floating on air" [4,7]. Periosteal new bone formation and slight root resorption also may be present [9]. Cases may present as aggressive periodontitis lesions that do not respond to routine periodontal therapy [10], despite the presence of bacteria typically associated with periodontitis [11].

When periodontal involvement is suspected to be a manifestation of LCH, biopsy of the gingiva or periodontal tissues is needed [7,10-12]. The diagnostic evaluation for children in whom a diagnosis of LCH is being considered is extensive and should be performed in consultation with a pediatric hematologist. (See "Clinical manifestations, pathologic features, and diagnosis of Langerhans cell histiocytosis", section on 'Diagnosis'.)

The treatment of LCH, discussed in detail separately, can result in the loss or arrested development of teeth. (See "Clinical manifestations, pathologic features, and diagnosis of Langerhans cell histiocytosis", section on 'Lytic bone lesions' and "Treatment of non-pulmonary Langerhans cell histiocytosis", section on 'Adults'.)

LEUKEMIA — Leukemia, particularly myelogenous leukemia, can cause gingival enlargement because of infiltration of the gingival tissues [13,14]. Leukemic gingival enlargement is typically painless, shiny, red, and edematous (picture 2); bleeding is common and can make it difficult to maintain oral hygiene. Necrotic ulceration and involvement of the underlying bone also can occur [15]. The inflammation that results may act as a stimulus for further gingival swelling [16]. Additional symptoms include fever, malaise, easy bruising or bleeding, and bone or joint pain.

The diagnosis of leukemia should be considered in patients who have hemorrhagic gingival edema and anemia, thrombocytopenia, or abnormal leukocyte and differential counts on complete blood count. (See "Overview of the clinical presentation and diagnosis of acute lymphoblastic leukemia/lymphoma in children".)

As in Langerhans cell histiocytosis, the treatment of leukemia (both lymphocytic and myelogenous leukemia) can have oral complications, including [17-19]:

Mucositis (picture 3)

Oral infection with candida, herpes simplex virus, or other opportunistic organisms

Gingival inflammation (gingivitis)

Spontaneous gingival bleeding (because of thrombocytopenia)

Gingival squamous cell carcinoma (as a complication of graft versus host disease in hematopoietic cell transplant recipients)

The chemotherapy-induced oral complications in patients with leukemia are more prevalent immediately after administration of chemotherapy [20]. They occur irrespective of the chemotherapy protocol used [20].

The oral complications of chemotherapy can be diminished by aggressive preventive care, including comprehensive oral examination before the initiation of cancer therapy [21-23]. The oral cavity is a reservoir for many microorganisms with the potential to cause systemic infection in the immunocompromised host. In addition, dental plaque causes gingivitis and gingival bleeding. Careful brushing with a soft toothbrush should be continued throughout therapy. Although it has been recommended that toothbrushing be suspended or replaced by cleaning with sponge-tipped brushes ("toothettes") when platelet counts are low, these approaches are not adequate for plaque removal, and available evidence suggests problems are more likely to arise when oral hygiene is poor [19,24]. The prevention and treatment of chemotherapy-related mucositis are discussed in detail separately. (See "Oral toxicity associated with systemic anticancer therapy", section on 'Mucositis'.)

LEUKOCYTE-ADHESION DEFICIENCY SYNDROMES — Leukocyte-adhesion deficiency (LAD) syndromes are autosomal recessive disorders characterized by inability of the neutrophils to exit the circulation in response to inflammation, including inflammation related to periodontitis-associated species in the LAD subgingival microbiome. The migration defects include abnormal neutrophil motility, adherence, or rolling (table 1). (See "Leukocyte-adhesion deficiency".)

Patients with LAD may present with delayed separation of the umbilical cord or recurrent bacterial infections of the ears, sinuses, lungs, and skin. Wounds and abscesses heal poorly, and minimal pus is formed. The number of peripheral neutrophils is increased by their inability to leave the circulation and can be as high as 100,000/mm3. LAD is usually diagnosed on the basis of recurrent infection before oral manifestations occur.

Oral manifestations of LAD are seen in the early primary dentition and include severe gingival inflammation, rapid bone loss around nearly all teeth, and mobility and premature loss of teeth. The LAD-associated destruction of periodontal tissues is determined primarily by the unregulated localized increase of proinflammatory cytokines, not the lack of local antibacterial defenses [25]. The periodontitis associated with LAD has been called generalized prepubertal periodontitis in the dental literature [26].

The diagnosis and treatment of LAD are discussed separately. Meticulous oral hygiene is necessary to control the periodontal disease associated with LAD, but restoration of gingival health may require bone marrow transplantation [27]. In a case report, off-label use of anticytokine therapy dramatically reduced the periodontal pathologic features within weeks [28]. (See "Leukocyte-adhesion deficiency".)

NEUTROPENIA — Neutropenia is a hematologic disorder characterized by reduced numbers of circulating neutrophils. It is diagnosed when the absolute neutrophil count (ANC) is less than 1500/microL [29]. (See "Overview of neutropenia in children and adolescents", section on 'Definitions and normal values' and "Approach to the adult with unexplained neutropenia", section on 'Definitions and normal values'.)

Neutrophils are an important component of the host response to pathogenic dental plaque in the gingival sulcus, and patients with neutropenia are at risk for severe gingivitis and pronounced alveolar bone loss (picture 4). Periodontal disease occurs in the following types of childhood neutropenia:

Congenital neutropenia

Autoimmune neutropenia (AIN)

Cyclic neutropenia

Congenital — Congenital neutropenia occurs in several conditions where there is a marked decrease in (or lack of) circulating neutrophils from the time of birth. These conditions include infantile agranulocytosis (Kostmann syndrome), Shwachman-Diamond syndrome, myelokathexis, congenital dysgranulopoietic neutropenia, and the Chediak-Higashi syndrome. These are rare disorders, with an estimated frequency of two cases per million population [30]. (See "Congenital neutropenia".)

Children with congenital neutropenia are susceptible to recurrent infection, often due to staphylococci and streptococci. Oral lesions, otitis media, respiratory infection, cellulitis, and skin abscesses are the most common. These infections heal slowly and may be fatal. Oral manifestations of congenital neutropenia include ulcers, severe gingivitis, alveolar bone loss, gingival recession, tooth mobility, and premature tooth exfoliation. An observational study suggests that mutations in the elastase gene are particularly significant for the development of periodontal disease in patients with congenital neutropenia [31]. However, other genetic diseases whose phenotype includes congenital neutropenia in the absence of elastase gene mutations, such as Cohen syndrome [32], may also have significant periodontal involvement characterized by severe gingivitis, alveolar bone loss, and premature tooth loss [33].

The treatment of congenital neutropenia usually involves the administration of granulocyte colony-stimulating factor (G-CSF) [31] and is discussed in detail separately. (See "Congenital neutropenia", section on 'Treatment'.)

Autoimmune — AIN is caused by granulocyte-specific antibodies. AIN has been associated with a variety of underlying diseases, including viral infection, collagen vascular disease, primary abnormalities of B or T lymphocytes or natural killer cells, immune thrombocytopenia, and autoimmune hemolytic anemia [34]. In most cases, however, AIN is not associated with other illness or underlying disease and is referred to as chronic benign neutropenia of infancy and childhood [35,36]. (See "Immune neutropenia", section on 'Autoimmune neutropenia'.)

Benign neutropenia of infancy and childhood typically occurs in infants between the ages of 5 to 15 months, but the range extends from one month to adulthood [37]. Spontaneous recovery occurs within 24 months in the majority of patients (95 percent in one study) [35,36]. Until they recover, children with this disorder are subject to recurrent, albeit mild, infection [35,38]. Although the neutropenia is severe (ANC less than 500/microL), the ANC can rise temporarily in response to acute infection. This temporary increase in neutrophil count can help in attenuating the severity of acute infection but has little effect on periodontal disease, which is a chronic infection. Severe gingivitis and periodontal disease may result without preventive measures (picture 4) [39].

Cyclic neutropenia — Cyclic neutropenia is characterized by regular oscillations in the numbers of circulating neutrophils, monocytes, eosinophils, lymphocytes, and reticulocytes [40-42]. The cycles typically occur at 21-day intervals, but the intervals can range from 15 to 35 days. Neutrophil counts fluctuate between normal and less than 500/microL [42]. The monocyte, eosinophil, platelet, and reticulocyte oscillations usually fluctuate from normal to high levels, and the periodicity of these cycles is typically the same as that for the neutrophils [41]. During periods of neutropenia, the bone marrow is usually hypoplastic, with myelocyte arrest [43]. (See "Cyclic neutropenia".)

Cyclic neutropenia can have onset in childhood or adulthood. Childhood onset is more common and appears to be a genetic condition with autosomal dominant inheritance [42,44]. Among families with autosomal dominant disease, the spectrum of severity ranges from asymptomatic to life-threatening [44].

Periods of severe neutropenia typically last one week during each cycle; during these periods, patients are prone to malaise, fever, aphthous stomatitis, and occasionally serious cutaneous and subcutaneous infections [40,41]. The severity of infections varies in relation to the severity of neutropenia. Gingival inflammation, edema, and recession can occur; alveolar bone support may be lost in the preschool-age child, resulting in premature tooth mobility and loss (picture 5). Without vigilant management, death from infection is a possibility [43].

The diagnosis and treatment of cyclic neutropenia are discussed in detail separately. (See "Cyclic neutropenia".)

Dental management — Early dental referral and highly motivated caregivers are the keys to successful dental management of children with neutropenia. Neutropenia predisposes the child to hemorrhagic gingivitis and periodontal disease, but the progression of bone loss is because of the host response to pathogenic subgingival plaque. Thus, scrupulous oral hygiene, antimicrobial rinses, frequent professional tooth cleaning, and targeted antibiotic therapy can delay or halt periodontal bone loss.

Antibiotic therapy for neutropenic children with periodontal disease is determined by microbial culture and susceptibility testing of a pooled sample of the gingival crevicular fluid (ie, the inflammatory exudate from the periodontal tissues) if it is possible to obtain these studies. If it is not possible to obtain culture and susceptibility testing of a pooled sample of gingival crevicular fluid, empiric antimicrobial therapy is prudent. Appropriate empiric regimens include one of the following agents: amoxicillin, clindamycin, or cephalexin.

The organisms most commonly cultured in children with periodontal disease include Prevotella intermedia, Actinobacillus actinomycetemcomitans, Eikenella corrodens, and Capnocytophaga sputigena [45]. Eradication and control of these pathogens is essential in the treatment of periodontal disease. Periodic surveillance cultures will help to determine the need for repetition of antibiotic therapy.

The treatment of neutropenic children with periodontal disease is usually more successful in children with localized than with generalized periodontal disease; generalized periodontal disease may be refractory to antibiotic therapy without correction of the underlying neutrophil defect. Treatment of the underlying disorder with administration of G-CSF, and normalization of neutrophil counts, may not be sufficient to maintain oral health because of possible associated functional neutrophil defects; this underscores the significance of professional dental care for such patients [46].

CHRONIC GRANULOMATOUS DISEASE — Chronic granulomatous disease (CGD) is a rare primary immunodeficiency disorder caused by defective phagocyte function and characterized by life-threatening bacterial and fungal infections and granuloma formation. CGD is genetically heterogeneous (resulting from mutations in various genes involved in the nicotinamide adenine dinucleotide phosphate oxidase complex [MIM #306400, MIM #233690, MIM #233700, MIM #233710, MIM #613960]). Most patients are diagnosed before the age of five years.

Oral pathology includes periodontitis, severe gingivitis, oral ulcers, and oral candidiasis. Periodontal attachment loss may manifest in the primary or permanent dentition [47,48]. (See "Chronic granulomatous disease: Pathogenesis, clinical manifestations, and diagnosis".)

CHEDIAK-HIGASHI SYNDROME — Chediak-Higashi syndrome (CHS) (MIM #214500) is a rare primary immunodeficiency characterized by recurrent pyogenic infections, partial oculocutaneous albinism, and progressive neurologic abnormalities. CHS is caused by mutations in the LYST gene. Patients are typically identified in infancy or early childhood because of their unusual coloring (ie, lighter than normal skin and sparse light blond, gray, or white hair that often has a metallic sheen (picture 6)). Patients develop severe pyogenic infections of the skin, respiratory tract, and mucous membranes, and typically succumb to these infections if not treated with hematopoietic cell transplant by mid-childhood [49].

Periodontitis is the most common oral complication; other common oral complications include ulcerations and gingival/periodontal abscesses [50,51]. Children with CHS may present with premature loss of the primary dentition [50,51]. Children with CHS who have received hematopoietic cell transplantation or have atypical CHS disease are less likely to develop severe periodontitis or experience early tooth loss [52]. While some children with a mild systemic phenotype may benefit from routine periodontal therapy, the periodontal disease in CHS is often refractory to treatment, resulting in tooth loss [53,54]. When the tooth loss is managed with dental implant rehabilitation, peri-implantitis is frequent [51]. (See "Chediak-Higashi syndrome".)

DIABETES MELLITUS — Adults and children with type 1 and type 2 diabetes mellitus have an increased risk for and earlier onset of periodontal disease, probably related to altered immune function [55-59] and decreases in localized innate immunity defense mechanisms [60,61]. Periodontal disease is present in 10 to 15 percent of adolescents with type 1 diabetes. In children and adolescents with type 2 diabetes, periodontal destruction appears to be associated with components of the metabolic syndrome and beta cell function [62]. Poor metabolic control increases the risk of periodontal disease through altered neutrophil chemotaxis [63]. Children with poorly controlled diabetes tend to have poorer oral hygiene practices [64] and have an increased plaque index and more severe gingivitis than healthy children [65-68]. Poor glycemic control has also been associated with increased diversity of gingival microbiota in children with diabetes [69,70]. Puberty aggravates periodontal disease in children with diabetes [71]. Periodontal disease, in turn, worsens diabetes control [72]. Glucose control, oral hygiene, and early diagnosis and treatment of periodontal disease are important for the overall health of children with diabetes. Children with diabetes mellitus may have accelerated tooth eruption. (See "Anatomy and development of the teeth", section on 'Accelerated eruption'.)

Diabetes mellitus is associated with increased risk of peri-implantitis [73], although evidence suggests that implant survival rates are not affected by diabetes [74].

HYPOPHOSPHATASIA — Hypophosphatasia is a rare autosomal disease characterized by abnormal mineralization of bone and dental tissues [75-79]. It is caused by deficiency of tissue-nonspecific alkaline phosphatase due to mutations in the tissue-nonspecific alkaline phosphatase (TNSALP) gene [80]. The phenotypic appearance varies; the earlier the presentation, the more severe the disease. Early loss of primary incisors may be the first and only sign in mild disease (picture 7). Early tooth loss without generalized gingival bleeding and inflammation helps to distinguish hypophosphatasia from other causes of periodontal disease in children.

The severe forms of the disease are autosomal recessive and present in the perinatal period (usually lethal) and in infancy (MIM #241500). Patients with the infantile form present within the first six months of life with generalized skeletal demineralization, hypercalcemia, hypercalciuria, fractures, craniosynostosis, short extremities, poor weight gain, and respiratory infections [81]. These clinical features are reproduced in mice in which the genes for alkaline phosphatase have been deleted [82].

The childhood (MIM #241510) and adult (MIM #146300) forms are less severe than the infantile form and can be dominant or recessive [76,77,83,84]. They have variable penetrance and expression but typically present with premature loss of deciduous teeth. The extraoral manifestations of childhood hypophosphatasia include craniosynostosis, short stature, bone pain, spontaneous fractures, and scoliosis. Demineralization and rachitic changes can be seen on radiographs [81]. Muscle pain, stiffness, and proximal lower-limb weakness also may occur [85]. In the adult form, dental disease often precedes the onset of symptomatic osteomalacia.

Hypophosphatasia leads to complete absence or marked reduction in the amount of cementum covering the root's surface [86]. The absence of cementum prevents normal anchoring of the fibers of the periodontal ligament and leads to premature tooth mobility and loss. The periodontal microbiota of children with hypophosphatasia appear to be no different from that of healthy controls [87]. Lower alkaline phosphatase activity and lower capacity for forming mineralized nodules by pulpal cells in hypophosphatasia may contribute to dentin dysplasia [88].

The teeth are affected in the order of formation; those that form earliest are more severely involved. Approximately three-quarters of affected children have premature exfoliation of primary teeth. Exfoliation of the primary incisors typically occurs before four years of age and may occur as early as 18 months of age in more severe disease. The other primary teeth are affected to varying degrees, and the permanent dentition usually is normal [75].

Hypophosphatasia is diagnosed through blood sampling that demonstrates low serum alkaline phosphatase concentration or elevated concentrations of phosphoethanolamine and pyrophosphate. Affected patients also may have increased urinary excretion of phosphoethanolamine [67].

Enzyme replacement therapy (asfotase alfa) is available for perinatal/infantile- and juvenile-onset hypophosphatasia [89]. Asfotase alfa is administered by subcutaneous injection three or six times per week.

In several open-label prospective studies including more than 100 patients with perinatal-, infantile-, or juvenile-onset hypophosphatasia, enzyme replacement therapy was associated with improved overall survival, ventilator-free survival, growth, and bone mineralization compared with a historic cohort [89,90]. In animal studies, enzyme replacement therapy prevented or improved dental/alveolar pathology [91]. Although such improvements in hypophosphatasia have not yet been reported in human trials [92,93], positive dental outcomes have been noted in case reports of children with infantile and childhood-type perinatal hypophosphatasia who received asfotase alfa at various ages [79,94,95]. These include improved mineralization of teeth under formation, improved stability of loose teeth, absence of early tooth loss (ie, at ≤3.5 years of age), and stabilization of the periodontal condition [79,94,95]; the positive dental outcomes varied by child and age at onset of treatment.

Adverse effects of asfotase alfa include injection site reactions, hypersensitivity reactions, lipodystrophy, and ectopic calcification in the eyes and kidney [89,90]. Recurrence and worsening of disease-associated laboratory and radiographic biomarkers in association with neutralizing has been reported in post-marketing surveillance, suggesting the possibility of immune-mediated disease progression [96].

Palliative therapy for the infantile form may include correction of hypercalcemia (with calcitonin), reduction of hypercalciuria (with chlorothiazide), reduction of dietary intake of calcium and vitamin D, and reduced exposure to sunlight. Secondary rickets can be prevented through the administration of between 200 and 400 international units (IU) of vitamin D per day. Serial monitoring of 25-hydroxyvitamin D levels is necessary to monitor and titrate intake [81,85].

DOWN SYNDROME — Individuals with Down syndrome have increased susceptibility to periodontal disease. Periodontal disease may be present in the primary dentition and develops in most patients by 30 years of age. The severity of periodontal destruction is greater than can be attributed to the increased levels of plaque in these patients [97]. The subgingival microbiota of patients with Down syndrome who have periodontitis does not differ from that of patients without Down syndrome who have periodontitis [98]. However, children with Down syndrome have substantially higher prevalence of periodontal pathogens in the primary dentition, in the absence of any periodontal involvement [99]. The periodontal involvement in Down syndrome patients has negative effects on quality of life [100]. Down syndrome is associated with abnormalities in the immune system, particularly lymphocyte function, which may contribute to their increased susceptibility to periodontal disease [101]. Molecular studies suggest involvement of the PI3K-Akt signaling pathway in the development of periodontitis in patients with Down syndrome [102,103].

In patients with Down syndrome, mechanical nonsurgical periodontal therapy alone may not provide the expected reduction in periodontal pathogenic bacteria, suggesting the need for adjunctive antimicrobial therapy [104]. In a systematic review, early institution of periodontal care; supervision of oral hygiene by parents, caregivers, or institutional attendants; frequent dental visits; and addition of chemical adjuvants (eg, chlorhexidine, plaque disclosing agents) were associated with improved periodontal outcomes in children with Down syndrome [105]. Dental implant therapy is not contraindicated in Down syndrome patients, although dental implant survival may be reduced [106,107]. (See "Gingivitis and periodontitis in children and adolescents", section on 'Periodontitis' and "Down syndrome: Clinical features and diagnosis", section on 'Immunodeficiency'.)

In addition, patients with Down syndrome commonly have high attachment of the anterior mandibular frenum that is associated with gingival recession [97]. (See "Soft tissue lesions of the oral cavity in children", section on 'Abnormalities of the labial frena'.)

PAPILLON-LEFÈVRE SYNDROME — The Papillon-Lefèvre syndrome (PLS; MIM #245000) is characterized by premature loss of the primary and permanent teeth and hyperkeratosis of the palms (picture 8), soles, and sometimes of the knees and elbows. It is caused by loss-of-function mutations in the cathepsin C gene (CTSC) on chromosome 11q14 [108-110].

The periodontal inflammation begins soon after eruption of the primary teeth. Bone loss is rapid and severe; primary teeth are lost by three to five years of age and permanent teeth within a few years of eruption (picture 9). Rare cases with absence of periodontal involvement in the permanent dentition have been reported [111]. Screening for lack of urinary cathepsin C activity soon after birth may allow early diagnosis, before tooth eruption and development of periodontal disease [112].

The severity of disease may be related to immunologic and microbiologic factors. Patients with PLS have abnormalities in neutrophil and natural killer cell function [109,110,113-115]. Molecular mechanisms implicated in the periodontal pathogenesis include the deficient processing and lack of cathelicidin (LL37) in gingival fluid [116]. The organisms typically cultured from the gingival sulcus of patients with PLS are similar to those cultured from children who have neutropenia, and include A. actinomycetemcomitans, Capnocytophaga species, Fusobacterium nucleatum, E. corrodens, and Aggregatibacter actinomycetemcomitans [116-118]. However, there are reports of patients with PLS who have salivary abundance of uncommon organisms (Archaea) [119].

Recommended periodontal treatment of young children with PLS includes identification of specific periodontal pathogens and antibiotic therapy targeted to these microorganisms if culture and susceptibility testing is available [120]. If culture and susceptibility testing is not available, empiric therapy with amoxicillin-clavulanate and metronidazole is reasonable [121]. In cases where antimicrobial therapy is unsuccessful, extraction of all erupted teeth or treatment with retinoids has been reported to preserve the unerupted permanent teeth [117,120,122,123].

Under proper maintenance care, use of dental implants to treat tooth loss in patients with PLS appears to be successful [124]. However, in the absence of consistent supportive periodontal therapy, peri-implantitis and implant loss are common [125].

PERIODONTAL TYPES OF EHLERS-DANLOS SYNDROME — Ehlers-Danlos syndrome (EDS) periodontal type 1 (MIM #130080) and EDS periodontal type 2 (MIM #617174) are types of EDS characterized by severe onset of periodontal disease and premature tooth loss in childhood [126,127]. EDS periodontal type 1 is caused by mutations of the C1R gene and EDS periodontal type 2 is caused by mutations of the C1S gene [127].

Patients with EDS have reported a delay between the first oral manifestation and diagnosis, often exceeding 15 years [128,129]. Both periodontal types of EDS have autosomal dominant inheritance and should be considered in the differential diagnosis of patients with dominant familial forms of severe periodontal disease with early onset. Generalized lack of attached gingiva is considered a pathognomonic feature in children and adults with periodontal types of EDS [130]. Patients with periodontal types of EDS who receive dental implants to replace lost teeth are at high risk for peri-implant disease and associated implant failure [131]. EDS-associated oral conditions have a negative impact on the patients' quality of life [128].

Patients with periodontal types of EDS may lack findings of classic EDS (eg, joint hypermobility, hyperextensible skin, tissue fragility), but signs of collagen disorganization are present microscopically. Periodontal EDS has been associated with adult-onset leukoencephalopathy [132] and vascular complications [133]. (See "Clinical manifestations and diagnosis of Ehlers-Danlos syndromes".)

Periodontal manifestations have been rarely reported in other types of EDS [134]. The coexistence of different forms of EDS in an individual is possible but extremely rare [135,136].

KINDLER EPIDERMOLYSIS BULLOSA — Kindler epidermolysis bullosa (KEB; MIM #173650) is a rare autosomal recessive type of epidermolysis bullosa associated with increased risk of mucocutaneous malignancy. (See "Kindler epidermolysis bullosa".)

Patients with KEB have spontaneous gingival bleeding, fragile and often desquamative gingiva, mild to severe gingival inflammation, and high-grade periodontitis characterized by early-onset and rapid progression [137-141]. The periodontitis appears to manifest following eruption of the permanent dentition, with minimal attachment loss reported in patients younger than 10 years of age [139].

The periodontitis of KEB is not necessarily associated with the typical virulent periodontopathogenic bacteria found in other forms of aggressive periodontitis, underscoring the significance of host susceptibility [137,139]. Histopathologically, gingival tissues exhibit disorganization at the basement membrane, blistering at the level of lamina lucida, and abnormal deposition of type VII collagen [138,142]. The adhesion of the junctional epithelium to the tooth may be severely compromised [140].

Limited evidence suggests that standard mechanical periodontal therapy followed by regular periodontal maintenance may result in moderate success when treating KEB patients [140,141], although the gingiva and oral mucosa may remain fragile and abnormal (lichenoid) in appearance [140]. Regular dental visits are crucial for the oral/periodontal management of patients with KEB [143].

INFECTIONS — Infections associated with oral lesions are discussed separately. (See "Soft tissue lesions of the oral cavity in children", section on 'Infections'.)

SUMMARY

Langerhans cell histiocytosis (LCH) – Dental presentations of LCH include eruption of the primary molars at or soon after birth (picture 1), aggressive periodontitis lesions that do not respond to routine periodontal therapy, and dental radiographs demonstrating discrete, destructive bone lesions that make the teeth appear to be "floating on air." (See 'Langerhans cell histiocytosis' above and "Clinical manifestations, pathologic features, and diagnosis of Langerhans cell histiocytosis".)

Leukemia – Leukemia should be considered in patients who have hemorrhagic gingival edema (picture 2) and anemia, thrombocytopenia, or abnormal leukocyte and differential counts on complete blood count. (See 'Leukemia' above and "Overview of the clinical presentation and diagnosis of acute lymphoblastic leukemia/lymphoma in children".)

Leukocyte-adhesion deficiency (LAD) syndromes – Oral manifestations of LAD syndromes, which are seen in the early primary dentition, include severe gingival inflammation, rapid bone loss around nearly all teeth, and mobility and premature loss of teeth. (See 'Leukocyte-adhesion deficiency syndromes' above and "Leukocyte-adhesion deficiency".)

Neutropenia – Children with congenital, autoimmune, or cyclic neutropenia are predisposed to hemorrhagic gingivitis and periodontal disease (picture 4), potentially complicated by alveolar bone loss, tooth mobility (picture 5), and premature exfoliation. Scrupulous oral hygiene, antimicrobial rinses, frequent professional tooth cleaning, and targeted antibiotic therapy are the keys to successful dental management. (See 'Neutropenia' above and "Congenital neutropenia" and "Immune neutropenia", section on 'Autoimmune neutropenia' and "Cyclic neutropenia".)

Chronic granulomatous disease (CGD) – Oral manifestations of CGD include severe gingivitis, oral ulcers, oral candidiasis, and periodontitis of the primary and permanent dentition. (See 'Chronic granulomatous disease' above and "Chronic granulomatous disease: Pathogenesis, clinical manifestations, and diagnosis".)

Chediak-Higashi syndrome (CHS) – Children with CHS may present with severe pyogenic infections, oral ulcerations, gingivitis and periodontitis of both primary and permanent dentition. Periodontitis in CHS is often resistant to treatment. (See 'Chediak-Higashi syndrome' above and "Chediak-Higashi syndrome".)

Diabetes mellitus – Patients with type 1 and type 2 diabetes mellitus have an increased risk for and earlier onset of periodontal disease. Poor metabolic control increases the risk of periodontal disease. (See 'Diabetes mellitus' above.)

Hypophosphatasia – Hypophosphatasia is a rare disease characterized by abnormal mineralization of bone and dental tissues. Oral manifestations include premature loss of deciduous teeth. Exfoliation of the primary incisors typically occurs before four years of age and may occur as early as 18 months of age in more severe disease (picture 7). (See 'Hypophosphatasia' above.)

Down syndrome – Individuals with Down syndrome have increased susceptibility to periodontal disease. (See 'Down syndrome' above and "Down syndrome: Clinical features and diagnosis".)

Ehlers-Danlos syndrome – Patients with periodontal types of Ehlers-Danlos syndrome experience premature tooth loss because of periodontal disease and are at high risk for peri-implant disease and dental implant failure. (See 'Periodontal types of Ehlers-Danlos syndrome' above.)

Papillon-Lefèvre syndrome – The Papillon-Lefèvre syndrome is characterized by premature loss of the primary and permanent teeth and hyperkeratosis of the palms, soles, and sometimes of the knees and elbows. Periodontal inflammation begins soon after eruption of the primary teeth. Bone loss is rapid and severe; primary teeth are lost by three to five years of age and permanent teeth within a few years of eruption (picture 9). (See 'Papillon-Lefèvre syndrome' above.)

Kindler epidermolysis bullosa – Patients with Kindler epidermolysis bullosa have spontaneous gingival bleeding, fragile and often desquamative gingiva, mild to severe gingival inflammation, and aggressive (early-onset) periodontitis, characterized by rapid progression. (See 'Kindler epidermolysis bullosa' above.)

  1. Laskaris G, Tatakis DN, Stoufi E. Periodontal manifestations of local and systemic diseases: Colour atlas and text, Springer, Berlin 2022.
  2. Jepsen S, Caton JG, Albandar JM, et al. Periodontal manifestations of systemic diseases and developmental and acquired conditions: Consensus report of workgroup 3 of the 2017 World Workshop on the Classification of Periodontal and Peri-Implant Diseases and Conditions. J Clin Periodontol 2018; 45 Suppl 20:S219.
  3. Faustino ISP, Fernandes PM, Pontes HAR, et al. Langerhans cell histiocytosis in the oral and maxillofacial region: An update. J Oral Pathol Med 2021; 50:565.
  4. Henry RJ, Sweeney EA. Langerhans' cell histiocytosis: case reports and literature review. Pediatr Dent 1996; 18:11.
  5. Hartman KS. Histiocytosis X: a review of 114 cases with oral involvement. Oral Surg Oral Med Oral Pathol 1980; 49:38.
  6. Ardekian L, Peled M, Rosen D, et al. Clinical and radiographic features of eosinophilic granuloma in the jaws: review of 41 lesions treated by surgery and low-dose radiotherapy. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1999; 87:238.
  7. Guiglia R, Pizzo G, Aricò M, et al. Bifocal manifestation of eosinophilic granuloma in a pediatric patient. Med Sci Monit 2009; 15:CS95.
  8. Neves-Silva R, Fernandes DT, Fonseca FP, et al. Oral manifestations of Langerhans cell histiocytosis: A case series. Spec Care Dentist 2018; 38:426.
  9. Dagenais M, Pharoah MJ, Sikorski PA. The radiographic characteristics of histiocytosis X. A study of 29 cases that involve the jaws. Oral Surg Oral Med Oral Pathol 1992; 74:230.
  10. Silvestros SS, Mamalis AA, Sklavounou AD, et al. Eosinophilic granuloma masquerading as aggressive periodontitis. J Periodontol 2006; 77:917.
  11. Torrungruang K, Sittisomwong S, Rojanasomsith K, et al. Langerhans' cell histiocytosis in a 5-year-old girl: evidence of periodontal pathogens. J Periodontol 2006; 77:728.
  12. Klein F, Krigar D, Petzoldt D, Eickholz P. Periodontal manifestation of Langerhans' cell histiocytosis in a young man: case report with a 24-month follow-up. Quintessence Int 2006; 37:175.
  13. Delaney JE, Keels MA. Pediatric oral pathology. Soft tissue and periodontal conditions. Pediatr Clin North Am 2000; 47:1125.
  14. Cammarata-Scalisi F, Girardi K, Strocchio L, et al. Oral Manifestations and Complications in Childhood Acute Myeloid Leukemia. Cancers (Basel) 2020; 12.
  15. Weckx LL, Hidal LB, Marcucci G. Oral manifestations of leukemia. Ear Nose Throat J 1990; 69:341.
  16. Oral Pathology: Clinical-Pathologic Correlations, 2nd, Regezi JA, Sciubba J (Eds), WB Saunders, Philadelphia 1993. p.196.
  17. Peterson DE, D'Ambrosio JA. Nonsurgical management of head and neck cancer patients. Dent Clin North Am 1994; 38:425.
  18. Otsubo H, Yokoe H, Miya T, et al. Gingival squamous cell carcinoma in a patient with chronic graft-versus-host disease. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1997; 84:171.
  19. Ponce-Torres E, Ruíz-Rodríguez Mdel S, Alejo-González F, et al. Oral manifestations in pediatric patients receiving chemotherapy for acute lymphoblastic leukemia. J Clin Pediatr Dent 2010; 34:275.
  20. de Oliveira Lula EC, de Oliveira Lula CE, Alves CM, et al. Chemotherapy-induced oral complications in leukemic patients. Int J Pediatr Otorhinolaryngol 2007; 71:1681.
  21. Consensus statement: oral complications of cancer therapies. National Institutes of Health Consensus Development Panel. NCI Monogr 1990; :3.
  22. Childers NK, Stinnett EA, Wheeler P, et al. Oral complications in children with cancer. Oral Surg Oral Med Oral Pathol 1993; 75:41.
  23. Sonis S, Kunz A. Impact of improved dental services on the frequency of oral complications of cancer therapy for patients with non-head-and-neck malignancies. Oral Surg Oral Med Oral Pathol 1988; 65:19.
  24. da Fonseca MA. Pediatric bone marrow transplantation: oral complications and recommendations for care. Pediatr Dent 1998; 20:386.
  25. Moutsopoulos NM, Konkel J, Sarmadi M, et al. Defective neutrophil recruitment in leukocyte adhesion deficiency type I disease causes local IL-17-driven inflammatory bone loss. Sci Transl Med 2014; 6:229ra40.
  26. Watanabe K. Prepubertal periodontitis: a review of diagnostic criteria, pathogenesis, and differential diagnosis. J Periodontal Res 1990; 25:31.
  27. Roberts MW, Atkinson JC. Oral manifestations associated with leukocyte adhesion deficiency: a five-year case study. Pediatr Dent 1990; 12:107.
  28. Moutsopoulos NM, Zerbe CS, Wild T, et al. Interleukin-12 and Interleukin-23 Blockade in Leukocyte Adhesion Deficiency Type 1. N Engl J Med 2017; 376:1141.
  29. Halai H, Somani C, Donos N, Nibali L. Periodontal status of children with primary immunodeficiencies: a systematic review. Clin Oral Investig 2020; 24:1939.
  30. Berrocal T, Simón MJ, al-Assir I, et al. Shwachman-Diamond syndrome: clinical, radiological and sonographic findings. Pediatr Radiol 1995; 25:356.
  31. Ye Y, Carlsson G, Wondimu B, et al. Mutations in the ELANE gene are associated with development of periodontitis in patients with severe congenital neutropenia. J Clin Immunol 2011; 31:936.
  32. Duplomb L, Duvet S, Picot D, et al. Cohen syndrome is associated with major glycosylation defects. Hum Mol Genet 2014; 23:2391.
  33. Alaluusua S, Kivitie-Kallio S, Wolf J, et al. Periodontal findings in Cohen syndrome with chronic neutropenia. J Periodontol 1997; 68:473.
  34. Logue GL, Shimm DS. Autoimmune granulocytopenia. Annu Rev Med 1980; 31:191.
  35. Bux J, Behrens G, Jaeger G, Welte K. Diagnosis and clinical course of autoimmune neutropenia in infancy: analysis of 240 cases. Blood 1998; 91:181.
  36. Lalezari P, Khorshidi M, Petrosova M. Autoimmune neutropenia of infancy. J Pediatr 1986; 109:764.
  37. Bux J, Kissel K, Nowak K, et al. Autoimmune neutropenia: clinical and laboratory studies in 143 patients. Ann Hematol 1991; 63:249.
  38. Neglia JP, Watterson J, Clay M, et al. Autoimmune neutropenia of infancy and early childhood. Pediatr Hematol Oncol 1993; 10:369.
  39. Dixon CC, Thomson FJ, Barry SM. Oral Manifestations of Autoimmune Neutropenia: A Case Report. J Clin Pediatr Dent 2019; 43:46.
  40. Wright DG, Dale DC, Fauci AS, Wolff SM. Human cyclic neutropenia: clinical review and long-term follow-up of patients. Medicine (Baltimore) 1981; 60:1.
  41. Haurie C, Dale DC, Mackey MC. Cyclical neutropenia and other periodic hematological disorders: a review of mechanisms and mathematical models. Blood 1998; 92:2629.
  42. Dale DC, Hammond WP 4th. Cyclic neutropenia: a clinical review. Blood Rev 1988; 2:178.
  43. Lange RD, Jones JB. Cyclic neutropenia. Review of clinical manifestations and management. Am J Pediatr Hematol Oncol 1981; 3:363.
  44. Palmer SE, Stephens K, Dale DC. Genetics, phenotype, and natural history of autosomal dominant cyclic hematopoiesis. Am J Med Genet 1996; 66:413.
  45. Delaney JE, Kornman KS. Microbiology of subgingival plaque from children with localized prepubertal periodontitis. Oral Microbiol Immunol 1987; 2:71.
  46. Carlsson G, Wahlin YB, Johansson A, et al. Periodontal disease in patients from the original Kostmann family with severe congenital neutropenia. J Periodontol 2006; 77:744.
  47. Buduneli N, Baylas H, Aksu G, Kütükçüler N. Prepubertal periodontitis associated with chronic granulomatous disease. J Clin Periodontol 2001; 28:589.
  48. Cohen MS, Leong PA, Simpson DM. Phagocytic cells in periodontal defense. Periodontal status of patients with chronic granulomatous disease of childhood. J Periodontol 1985; 56:611.
  49. Carneiro IM, Rodrigues A, Pinho L, et al. Chediak-Higashi syndrome: Lessons from a single-centre case series. Allergol Immunopathol (Madr) 2019; 47:598.
  50. Rezende KM, Canela AH, Ortega AO, et al. Chediak-Higashi syndrome and premature exfoliation of primary teeth. Braz Dent J 2013; 24:667.
  51. de Arruda JAA, Sousa-Neto SS, Abreu LG, et al. Oral manifestations of Chediak-Higashi syndrome: A systematic review. Dis Mon 2023; 69:101356.
  52. Thumbigere Math V, Rebouças P, Giovani PA, et al. Periodontitis in Chédiak-Higashi Syndrome: An Altered Immunoinflammatory Response. JDR Clin Trans Res 2018; 3:35.
  53. Bailleul-Forestier I, Monod-Broca J, Benkerrou M, et al. Generalized periodontitis associated with Chédiak-Higashi syndrome. J Periodontol 2008; 79:1263.
  54. Shibutani T, Gen K, Shibata M, et al. Long-term follow-up of periodontitis in a patient with Chédiak-Higashi syndrome. A case report. J Periodontol 2000; 71:1024.
  55. Zainal Abidin Z, Zainuren ZA, Noor E, et al. Periodontal health status of children and adolescents with diabetes mellitus: a systematic review and meta-analysis. Aust Dent J 2021; 66 Suppl 1:S15.
  56. Grossi SG, Genco RJ, Machtei EE, et al. Assessment of risk for periodontal disease. II. Risk indicators for alveolar bone loss. J Periodontol 1995; 66:23.
  57. Taylor GW, Burt BA, Becker MP, et al. Non-insulin dependent diabetes mellitus and alveolar bone loss progression over 2 years. J Periodontol 1998; 69:76.
  58. Lalla E, Cheng B, Lal S, et al. Periodontal changes in children and adolescents with diabetes: a case-control study. Diabetes Care 2006; 29:295.
  59. Li J, Wang J, Song X, et al. Effect of type 2 diabetes mellitus and periodontitis on the Th1/Th2 and Th17/Treg paradigm. Am J Dent 2022; 35:55.
  60. Yilmaz D, Caglayan F, Buber E, et al. Gingival crevicular fluid levels of human beta-defensin-1 in type 2 diabetes mellitus and periodontitis. Clin Oral Investig 2018; 22:2135.
  61. Yilmaz D, Yilmaz N, Polat R, et al. Salivary levels of hBDs in children and adolescents with type 1 diabetes mellitus and gingivitis. Clin Oral Investig 2022; 26:4897.
  62. Merchant AT, Jethwani M, Choi YH, et al. Associations between periodontal disease and selected risk factors of early complications among youth with type 1 and type 2 diabetes: a pilot study. Pediatr Diabetes 2011; 12:529.
  63. Lalla E, Cheng B, Lal S, et al. Diabetes-related parameters and periodontal conditions in children. J Periodontal Res 2007; 42:345.
  64. Merchant AT, Oranbandid S, Jethwani M, et al. Oral care practices and A1c among youth with type 1 and type 2 diabetes. J Periodontol 2012; 83:856.
  65. Harrison R, Bowen WH. Periodontal health, dental caries, and metabolic control in insulin-dependent diabetic children and adolescents. Pediatr Dent 1987; 9:283.
  66. de Pommereau V, Dargent-Paré C, Robert JJ, Brion M. Periodontal status in insulin-dependent diabetic adolescents. J Clin Periodontol 1992; 19:628.
  67. Lundgren T, Westphal O, Bolme P, et al. Retrospective study of children with hypophosphatasia with reference to dental changes. Scand J Dent Res 1991; 99:357.
  68. Karjalainen KM, Knuuttila ML. The onset of diabetes and poor metabolic control increases gingival bleeding in children and adolescents with insulin-dependent diabetes mellitus. J Clin Periodontol 1996; 23:1060.
  69. Jensen ED, Selway CA, Allen G, et al. Early markers of periodontal disease and altered oral microbiota are associated with glycemic control in children with type 1 diabetes. Pediatr Diabetes 2021; 22:474.
  70. Chakraborty P, Chowdhury R, Bhakta A, et al. Microbiology of periodontal disease in adolescents with Type 1 diabetes. Diabetes Metab Syndr 2021; 15:102333.
  71. Chakraborty P, Mukhopadhyay P, Bhattacharjee K, et al. Periodontal Disease in Type 1 Diabetes Mellitus: Influence of Pubertal Stage and Glycemic Control. Endocr Pract 2021; 27:765.
  72. Lakschevitz F, Aboodi G, Tenenbaum H, Glogauer M. Diabetes and periodontal diseases: interplay and links. Curr Diabetes Rev 2011; 7:433.
  73. Monje A, Catena A, Borgnakke WS. Association between diabetes mellitus/hyperglycaemia and peri-implant diseases: Systematic review and meta-analysis. J Clin Periodontol 2017; 44:636.
  74. de Oliveira-Neto OB, Santos IO, Barbosa FT, et al. Quality assessment of systematic reviews regarding dental implant placement on diabetic patients: an overview of systematic reviews. Med Oral Patol Oral Cir Bucal 2019; 24:e483.
  75. Chapple IL. Hypophosphatasia: dental aspects and mode of inheritance. J Clin Periodontol 1993; 20:615.
  76. Whyte MP, Teitelbaum SL, Murphy WA, et al. Adult hypophosphatasia. Clinical, laboratory, and genetic investigation of a large kindred with review of the literature. Medicine (Baltimore) 1979; 58:329.
  77. Fallon MD, Teitelbaum SL, Weinstein RS, et al. Hypophosphatasia: clinicopathologic comparison of the infantile, childhood, and adult forms. Medicine (Baltimore) 1984; 63:12.
  78. Moore CA, Curry CJ, Henthorn PS, et al. Mild autosomal dominant hypophosphatasia: in utero presentation in two families. Am J Med Genet 1999; 86:410.
  79. Bowden SA, Foster BL. Alkaline Phosphatase Replacement Therapy for Hypophosphatasia in Development and Practice. Adv Exp Med Biol 2019; 1148:279.
  80. Taillandier A, Lia-Baldini AS, Mouchard M, et al. Twelve novel mutations in the tissue-nonspecific alkaline phosphatase gene (ALPL) in patients with various forms of hypophosphatasia. Hum Mutat 2001; 18:83.
  81. Wappner. RS. Inborn errors associated with faulty bone mineralization. In: Oski's Pediatrics: Principles and Practice, 4th ed, McMillan JA, Feigin RD, DeAngelis C, Jones MD (Eds), Lippincott, Williams & Wilkins, Philadelphia 2006. p.2238.
  82. Fedde KN, Blair L, Silverstein J, et al. Alkaline phosphatase knock-out mice recapitulate the metabolic and skeletal defects of infantile hypophosphatasia. J Bone Miner Res 1999; 14:2015.
  83. Seshia SS, Derbyshire G, Haworth JC, Hoogstraten J. Myopathy with hypophosphatasia. Arch Dis Child 1990; 65:130.
  84. Lepe X, Rothwell BR, Banich S, Page RC. Absence of adult dental anomalies in familial hypophosphatasia. J Periodontal Res 1997; 32:375.
  85. Barcia JP, Strife CF, Langman CB. Infantile hypophosphatasia: treatment options to control hypercalcemia, hypercalciuria, and chronic bone demineralization. J Pediatr 1997; 130:825.
  86. van den Bos T, Handoko G, Niehof A, et al. Cementum and dentin in hypophosphatasia. J Dent Res 2005; 84:1021.
  87. Valenza G, Burgemeister S, Girschick H, et al. Analysis of the periodontal microbiota in childhood-type hypophosphatasia. Int J Med Microbiol 2006; 296:493.
  88. Liu H, Li J, Lei H, et al. Genetic etiology and dental pulp cell deficiency of hypophosphatasia. J Dent Res 2010; 89:1373.
  89. US Food and Drug Administration. FDA approves new treatment for rare metabolic disorder. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm468836.htm (Accessed on October 28, 2015).
  90. Whyte MP, Madson KL, Phillips D, et al. Asfotase alfa therapy for children with hypophosphatasia. JCI Insight 2016; 1:e85971.
  91. Gasque KC, Foster BL, Kuss P, et al. Improvement of the skeletal and dental hypophosphatasia phenotype in Alpl-/- mice by administration of soluble (non-targeted) chimeric alkaline phosphatase. Bone 2015; 72:137.
  92. Whyte MP, Rockman-Greenberg C, Ozono K, et al. Asfotase Alfa Treatment Improves Survival for Perinatal and Infantile Hypophosphatasia. J Clin Endocrinol Metab 2016; 101:334.
  93. Okawa R, Iijima O, Kishino M, et al. Gene therapy improves dental manifestations in hypophosphatasia model mice. J Periodontal Res 2017; 52:471.
  94. Okawa R, Matayoshi S, Kariya R, et al. Effects of Enzyme Replacement Therapy for Primary Teeth in a Patient with Infantile Hypophosphatasia. J Clin Pediatr Dent 2020; 44:348.
  95. Okawa R, Kokomoto K, Nakano K. Dental effects of enzyme replacement therapy in case of childhood-type hypophosphatasia. BMC Oral Health 2021; 21:323.
  96. STRENSIQ (asfotase alfa) injection. US Food and Drug Administration (FDA) approved product information. Revised June, 2020. US Food & Drug Administration. Available online http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm (Accessed on October 20, 2020).
  97. Reuland-Bosma W, van Dijk J. Periodontal disease in Down's syndrome: a review. J Clin Periodontol 1986; 13:64.
  98. Nóvoa L, Sánchez MDC, Blanco J, et al. The Subgingival Microbiome in Patients with Down Syndrome and Periodontitis. J Clin Med 2020; 9.
  99. Vocale C, Montevecchi M, D'Alessandro G, et al. Subgingival periodontal pathogens in Down syndrome children without periodontal breakdown. A case-control study on deciduous teeth. Eur J Paediatr Dent 2021; 22:309.
  100. Amaral Loureiro AC, Oliveira Costa F, Eustáquio da Costa J. The impact of periodontal disease on the quality of life of individuals with Down syndrome. Downs Syndr Res Pract 2007; 12:50.
  101. Kusters MA, Verstegen RH, Gemen EF, de Vries E. Intrinsic defect of the immune system in children with Down syndrome: a review. Clin Exp Immunol 2009; 156:189.
  102. Fernández M, de Coo A, Quintela I, et al. Genetic Susceptibility to Periodontal Disease in Down Syndrome: A Case-Control Study. Int J Mol Sci 2021; 22.
  103. Chen Y, Yu X, Kong J. Identification of Neuropeptides as Potential Crosstalks Linking Down Syndrome and Periodontitis Revealed by Transcriptomic Analyses. Dis Markers 2021; 2021:7331821.
  104. Tanaka MH, Rodrigues TO, Finoti LS, et al. The effect of conventional mechanical periodontal treatment on red complex microorganisms and clinical parameters in Down syndrome periodontitis patients: a pilot study. Eur J Clin Microbiol Infect Dis 2015; 34:601.
  105. Ferreira R, Michel RC, Greghi SL, et al. Prevention and Periodontal Treatment in Down Syndrome Patients: A Systematic Review. PLoS One 2016; 11:e0158339.
  106. Najeeb S, Khurshid Z, Siddiqui F, et al. Outcomes of Dental Implant Therapy in Patients With Down Syndrome: A Systematic Review. J Evid Based Dent Pract 2017; 17:317.
  107. De Bruyn H, Glibert M, Matthijs L, et al. Clinical Guidelines for Implant Treatment in Patients with Down Syndrome. Int J Periodontics Restorative Dent 2019; 39:361–368.
  108. Papillon-Lefèvre syndrome. In: Mendelian Inheritance in Man. Johns Hopkins University. Available at: www.ncbi.nlm.nih.gov:80/entrez/dispomim.cgi?id=245000 (Accessed on February 02, 2008).
  109. Ghaffer KA, Zahran FM, Fahmy HM, Brown RS. Papillon-Lefèvre syndrome: neutrophil function in 15 cases fron 4 families in Egypt. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1999; 88:320.
  110. Firatli E, Tüzün B, Efeoğlu A. Papillon-Lefèvre syndrome. Analysis of neutrophil chemotaxis. J Periodontol 1996; 67:617.
  111. Umlauft J, Schnabl D, Blunder S, et al. Two patients with Papillon-Lefèvre syndrome without periodontal involvement of the permanent dentition. J Dermatol 2021; 48:537.
  112. Hamon Y, Legowska M, Fergelot P, et al. Analysis of urinary cathepsin C for diagnosing Papillon-Lefèvre syndrome. FEBS J 2016; 283:498.
  113. Ishikawa I, Umeda M, Laosrisin N. Clinical, bacteriological, and immunological examinations and the treatment process of two Papillon-Lefèvre syndrome patients. J Periodontol 1994; 65:364.
  114. Lundgren T, Parhar RS, Renvert S, Tatakis DN. Impaired cytotoxicity in Papillon-Lefèvre syndrome. J Dent Res 2005; 84:414.
  115. de Haar SF, Hiemstra PS, van Steenbergen MT, et al. Role of polymorphonuclear leukocyte-derived serine proteinases in defense against Actinobacillus actinomycetemcomitans. Infect Immun 2006; 74:5284.
  116. Eick S, Puklo M, Adamowicz K, et al. Lack of cathelicidin processing in Papillon-Lefèvre syndrome patients reveals essential role of LL-37 in periodontal homeostasis. Orphanet J Rare Dis 2014; 9:148.
  117. Preus H, Gjermo P. Clinical management of prepubertal periodontitis in 2 siblings with Papillon-Lefèvre syndrome. J Clin Periodontol 1987; 14:156.
  118. Wiebe CB, Häkkinen L, Putnins EE, et al. Successful periodontal maintenance of a case with Papillon-Lefèvre syndrome: 12-year follow-up and review of the literature. J Periodontol 2001; 72:824.
  119. Lettieri GM, Santiago LM, Lettieri GC, et al. Oral Phenotype and Salivary Microbiome of Individuals With Papillon-Lefèvre Syndrome. Front Cell Infect Microbiol 2021; 11:720790.
  120. Tinanoff N, Tempro P, Maderazo EG. Dental treatment of Papillon-Lefèvre syndrome: 15-year follow-up. J Clin Periodontol 1995; 22:609.
  121. Pacheco JJ, Coelho C, Salazar F, et al. Treatment of Papillon-Lefèvre syndrome periodontitis. J Clin Periodontol 2002; 29:370.
  122. Deeb AA, Bruce SN, Morris AA, Cheetham TD. Infantile hypophosphatasia: disappointing results of treatment. Acta Paediatr 2000; 89:730.
  123. Kressin S, Herforth A, Preis S, et al. Papillon-Lefèvre syndrome--successful treatment with a combination of retinoid and concurrent systematic periodontal therapy: case reports. Quintessence Int 1995; 26:795.
  124. Atarbashi-Moghadam F, Atarbashi-Moghadam S, Kazemifard S, et al. Oral rehabilitation of Papillon-Lefèvre syndrome patients by dental implants: a systematic review. J Korean Assoc Oral Maxillofac Surg 2020; 46:220.
  125. Nickles K, Krebs M, Schacher B, et al. Long-Term Results after Placing Dental Implants in Patients with Papillon-Lefèvre Syndrome: Results 2.5-20 Years after Implant Insertion. J Clin Med 2022; 11.
  126. Reinstein E, DeLozier CD, Simon Z, et al. Ehlers-Danlos syndrome type VIII is clinically heterogeneous disorder associated primarily with periodontal disease, and variable connective tissue features. Eur J Hum Genet 2013; 21:233.
  127. Kapferer-Seebacher I, Pepin M, Werner R, et al. Periodontal Ehlers-Danlos Syndrome Is Caused by Mutations in C1R and C1S, which Encode Subcomponents C1r and C1s of Complement. Am J Hum Genet 2016; 99:1005.
  128. Hanisch M, Blanck-Lubarsch M, Bohner L, et al. Oral Conditions and Oral Health-Related Quality of Life of People with Ehlers-Danlos Syndromes (EDS): A Questionnaire-Based Cross-Sectional Study. Medicina (Kaunas) 2020; 56.
  129. Cortés-Bretón Brinkmann J, García-Gil I, Lobato-Peña DM, et al. The key role of the dental practitioner in early diagnosis of periodontal Ehlers-Danlos syndromes: a rare case report of siblings. Quintessence Int 2021; 52:166.
  130. Kapferer-Seebacher I, Oakley-Hannibal E, Lepperdinger U, et al. Prospective clinical investigations of children with periodontal Ehlers-Danlos syndrome identify generalized lack of attached gingiva as a pathognomonic feature. Genet Med 2021; 23:316.
  131. Rinner A, Zschocke J, Schossig A, et al. High risk of peri-implant disease in periodontal Ehlers-Danlos Syndrome. A case series. Clin Oral Implants Res 2018; 29:1101.
  132. Kapferer-Seebacher I, Waisfisz Q, Boesch S, et al. Periodontal Ehlers-Danlos syndrome is associated with leukoencephalopathy. Neurogenetics 2019; 20:1.
  133. El Chehadeh S, Legrand A, Stoetzel C, et al. Periodontal (formerly type VIII) Ehlers-Danlos syndrome: Description of 13 novel cases and expansion of the clinical phenotype. Clin Genet 2021; 100:206.
  134. Kapferer-Seebacher I, Lundberg P, Malfait F, Zschocke J. Periodontal manifestations of Ehlers-Danlos syndromes: A systematic review. J Clin Periodontol 2017; 44:1088.
  135. Wu J, Yang J, Zhao J, et al. A Chinese family with periodontal Ehlers-Danlos syndrome associated with missense mutation in the C1R gene. J Clin Periodontol 2018; 45:1311.
  136. Stock F, Hanisch M, Lechner S, et al. Prepubertal Periodontitis in a Patient with Combined Classical and Periodontal Ehlers-Danlos Syndrome. Biomolecules 2021; 11.
  137. Wiebe CB, Silver JG, Larjava HS. Early-onset periodontitis associated with Weary-Kindler syndrome: a case report. J Periodontol 1996; 67:1004.
  138. Ricketts DN, Morgan CL, McGregor JM, Morgan PR. Kindler syndrome: a rare cause of desquamative lesions of the gingiva. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1997; 84:488.
  139. Wiebe CB, Penagos H, Luong N, et al. Clinical and microbiologic study of periodontitis associated with Kindler syndrome. J Periodontol 2003; 74:25.
  140. Wiebe CB, Petricca G, Häkkinen L, et al. Kindler syndrome and periodontal disease: review of the literature and a 12-year follow-up case. J Periodontol 2008; 79:961.
  141. Yıldırım TT, Kaya FA, Taşkesen M, et al. Aggressive periodontitis associated with Kindler syndrome in a large Kindler syndrome pedigree. Turk J Pediatr 2017; 59:56.
  142. Wiebe CB, Larjava HS. Abnormal deposition of type VII collagen in Kindler syndrome. Arch Dermatol Res 1999; 291:6.
  143. Krämer S, Lucas J, Gamboa F, et al. Clinical practice guidelines: Oral health care for children and adults living with epidermolysis bullosa. Spec Care Dentist 2020; 40 Suppl 1:3.
Topic 6281 Version 22.0

References

آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟